U.S. markets close in 2 hours 21 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
72.39+0.40 (+0.56%)
As of 1:39PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close71.98
Open72.68
Bid72.33 x 900
Ask72.43 x 800
Day's Range71.99 - 72.73
52 Week Range49.24 - 73.92
Volume655,910
Avg. Volume1,140,295
Market Cap168.192B
Beta (5Y Monthly)0.32
PE Ratio (TTM)29.40
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.04 (1.44%)
Ex-Dividend DateAug 14, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-13% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Novo Nordisk files for regulatory approval in the US of once-weekly semaglutide 2.0 mg for the treatment of type 2 diabetes

    Bagsværd, Denmark, 20 January 2021 – Novo Nordisk today announced the submission of a label expansion application to the US Food and Drug Administration (FDA) for the existing marketing authorisation for Ozempic®, a once-weekly glucagon-like peptide-1 (GLP-1) analogue, to introduce a new dose of 2.0 mg. Ozempic® is currently approved in the US in 0.5 mg and 1.0 mg doses for the treatment of type 2 diabetes in adults and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. The submission follows the application on 29 December 2020 for label extension to the European Medicines Agency (EMA). The submission is based on the results from the SUSTAIN FORTE trial, which included 961 people with type 2 diabetes in need of treatment intensification. In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c compared to semaglutide 1.0 mg. In the trial, both doses of semaglutide appeared to have safe and well-tolerated profiles. The most common adverse events were gastrointestinal, the vast majority were mild to moderate and diminished over time and were consistent with the GLP-1 receptor agonist class. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg. “We are excited about the regulatory submission of semaglutide 2.0 mg to the FDA,” said Mads Krogsgaard Thomsen, executive vice president and chief scientific officer of Novo Nordisk. “In the SUSTAIN programme most people achieved the treatment target of HbA1c levels below 7%. However, some patients need treatment intensification and with the 2.0 mg dose, more people with type 2 diabetes will be able to achieve treatment target”. About the SUSTAIN clinical programme The SUSTAIN clinical development programme for once-weekly subcutaneous semaglutide injection currently comprises 11 phase 3 global clinical trials, including a cardiovascular outcomes trial, involving more than 11,000 adults with type 2 diabetes. For more information about the SUSTAIN FORTE trial, please read the headline results here About Novo NordiskNovo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Media: Anne Margrethe Hauge+45 4442 3450amhg@novonordisk.comMichael Bachner (US)+1 609 664 7308mzyb@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.comValdemar Borum Svarrer+45 3079 0301jvls@novonordisk.comAnn Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.comMark Joseph Root+45 3079 4211mjhr@novonordisk.comKristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement No 3 / 2021 Attachment PR210120_SUSTAIN_Forte_FDA submission

  • GlobeNewswire

    Novo Nordisk A/S – Share repurchase programme

    Bagsværd, Denmark, 18 January 2021 – On 3 November 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020. Under the programme initiated 3 November 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.7 billion in the period from 4 November 2020 to 1 February 2021. Since the announcement as of 11 January 2021, the following transactions have been made: Number ofB sharesAveragepurchase priceTransactionvalue, DKKAccumulated, last announcement4,615,000 1,967,643,51711 January 2021120,000428.7051,443,72912 January 2021120,000429.5951,551,30013 January 2021120,000426.8151,216,63514 January 2021120,000434.1952,102,33715 January 2021120,000441.6452,996,729Accumulated under the programme5,215,000 2,226,954,247 The details for each transaction made under the share repurchase programme are published on novonordisk.com. With the transactions stated above, Novo Nordisk owns a total of 38,738,659 B shares of DKK 0.20 as treasury shares, corresponding to 1.6% of the share capital. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares. Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 15 January 2021, Novo Nordisk has since 5 February 2020 repurchased a total of 38,800,522 B shares at an average share price of DKK 425.00 per B share equal to a transaction value of DKK 16,490,383,717. Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 44,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube. Further information Media: Anne Margrethe Hauge+45 3079 3450amhg@novonordisk.comMichael Bachner (US)+1 609 664 7308mzyb@novonordisk.com Investors: Daniel Muusmann Bohsen+45 3075 2175dabo@novonordisk.comValdemar Borum Svarrer+45 3079 0301jvls@novonordisk.comAnn Søndermølle Rendbæk+45 3075 2253arnd@novonordisk.comMark Joseph Root+45 3079 4211mjhr@novonordisk.comKristoffer Due Berg (US)+1 609 235 2989krdb@novonordisk.com Company announcement No 2 / 2021 Attachment CA_210118_SafeHarbour

  • Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com
    PR Newswire

    Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com

    Today, Novo Nordisk announced the extension of its COVID-19 Patient Assistance Program until June 30, 2021, for those who have lost health insurance coverage because of a change in job status due to the pandemic.